144 related articles for article (PubMed ID: 14517494)
1. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
[TBL] [Abstract][Full Text] [Related]
3. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
[TBL] [Abstract][Full Text] [Related]
4. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
5. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Johansson LC; Frison L; Logren U; Fager G; Gustafsson D; Eriksson UG
Clin Pharmacokinet; 2003; 42(4):381-92. PubMed ID: 12648028
[TBL] [Abstract][Full Text] [Related]
6. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Sarich TC; Teng R; Peters GR; Wollbratt M; Homolka R; Svensson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(5):485-92. PubMed ID: 12739986
[TBL] [Abstract][Full Text] [Related]
7. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
Wolzt M; Wollbratt M; Svensson M; Wåhlander K; Grind M; Eriksson UG
Eur J Clin Pharmacol; 2003 Oct; 59(7):537-43. PubMed ID: 12955372
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
[TBL] [Abstract][Full Text] [Related]
9. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
Wernevik LC; Nyström P; Johnsson G; Nakanishi T; Eriksson UG
Clin Pharmacokinet; 2006; 45(1):77-84. PubMed ID: 16430312
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Fager G; Cullberg M; Eriksson-Lepkowska M; Frison L; Eriksson UG
Eur J Clin Pharmacol; 2003 Aug; 59(4):283-9. PubMed ID: 12845508
[TBL] [Abstract][Full Text] [Related]
12. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
Johansson LC; Andersson M; Fager G; Gustafsson D; Eriksson UG
Clin Pharmacokinet; 2003; 42(5):475-84. PubMed ID: 12739985
[TBL] [Abstract][Full Text] [Related]
13. Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran.
Wernevik LC; Nyström P; Andersson M; Johnsson G; Bylock A; Nakanishi T; Eriksson UG
Clin Pharmacokinet; 2006; 45(1):85-94. PubMed ID: 16430313
[TBL] [Abstract][Full Text] [Related]
14. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
Gustafsson D; Nyström J; Carlsson S; Bredberg U; Eriksson U; Gyzander E; Elg M; Antonsson T; Hoffmann K; Ungell A; Sörensen H; Någård S; Abrahamsson A; Bylund R
Thromb Res; 2001 Feb; 101(3):171-81. PubMed ID: 11228340
[TBL] [Abstract][Full Text] [Related]
15. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
Dorani H; Schützer KM; Sarich TC; Wall U; Logren U; Ohlsson L; Eriksson UG
Eur J Clin Pharmacol; 2007 Jun; 63(6):571-81. PubMed ID: 17387462
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Eriksson H; Eriksson UG; Frison L; Hansson PO; Held P; Holmström M; Hägg A; Jonsson T; Lapidus L; Leijd B; Stockelberg D; Säfwenberg U; Taghavi A; Thorsén M
Thromb Haemost; 1999 Mar; 81(3):358-63. PubMed ID: 10102460
[TBL] [Abstract][Full Text] [Related]
18. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of ximelagatran.
Wolzt M; Sarich TS; Eriksson UG
Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
